Editorial
The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab
Abstract
In an elegant study by Weide et al., baseline biomarkers to predict responses to anti-programmed death-1 (PD-1) (pembrolizumab) therapy in melanoma patients were investigated (1).
